Snapshot · Eli Lilly and Company (LLY)

Data as of 2026-10-18T09:25:35.996Z

Fundamentals check

Market cap

$1.18T

P/E (TTM)

42.1

Gross margin

83.4%

Net margin

33.5%

ROE

92.6%

R&D / revenue

18.3%

Dividend yield

0.5%

FCF yield

1.7%

Latest dividend: $1.73/share (ex-date 2026-08-14, quarterly)

Summary

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

How it makes money

Revenue mix, latest fiscal year

• Product93.5%
• Collaboration and Other Revenue6.5%

Recent Events

• 2026-10-16T14:38:00.000Zneutral

  Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

  分析报道，可能与公司药物前景相关，但不构成因果。

  Source: fool.com

• 2026-10-15T11:51:22.000Zpositive

  Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients

  恰逢新药数据公布，可能对长期增长预期有帮助。

  Source: benzinga.com

• 2026-10-15T03:45:31.000Znegative

  Eli Lilly and Company $LLY Stock Sold by Fairfield Financial Advisors LTD

  可能与机构减持相关，市场情绪或波动受影响，但因果不确定。

  Source: defenseworld.net

• 2026-10-14T00:00:00.000Zpositive

  Price move: LLY rose 3.6%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-19T00:00:00.000Zpositive

  Price move: LLY rose 4.5%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-05T00:00:00.000Zneutral

  LLY filed 10-Q

  可能与季度披露相关，恰逢市场关注最新财报，暂不确定对股价因果。

  Source: SEC EDGAR

• 2026-08-05T00:00:00.000Zpositive

  Price move: LLY rose 4.9%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-30T00:00:00.000Znegative

  Price move: LLY fell 4.5%

  LLY 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $1342.9 from 10 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-17SellJonsson Patrik(officer: EVP & President, LLY Int'l)6,500 shares
• 2026-08-10SellZakrowski Donald A(officer: SVP, Finance, & CAO)2,000 shares
• 2026-08-07SellHakim Anat(officer: EVP, GC & Secretary)5,000 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。